ASA Submits Recommendations to FDA for International Rescheduling of Cannabis

By | April 23, 2018

This week, we submitted comments relating to the efficacy and medical usefulness of cannabis as a medical treatment. In early April, the Food and Drug Administration (FDA) issued a notice in the federal register asking for public comments on cannabis and its derivatives. These comments will help inform the response of the United States to the World Health Organization in potentially reclassifying cannabis.

Read ASA’s Comments Here


Leave a Reply

Your email address will not be published. Required fields are marked *